Proton Pump Inhibitors and Fracture Risk: True Effect or Residual Confounding?

Author： Bodmer Michael Meier Christian Kraenzlin Marius E. Meier Christoph R.

ISSN： 0114-5916

Source： Drug Safety, Vol.33, Iss.10, 2010-10, pp. : 843-852

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prescribing Proton Pump Inhibitors: Is it Time To Pause and Rethink?

By Vakil Nimish

Drugs, Vol. 72, Iss. 4, 2012-03 ,pp. : 437-445

Adis International

Access to resources Recommend Favorite

Proton Pump Inhibitors: Do Differences in Pharmacokinetics Translate into Differences in Clinical Outcomes?

By Kwong Ming Fock

Clinical Pharmacokinetics, Vol. 47, Iss. 1, 2008-01 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite

Are Proton Pump Inhibitors Safe during Pregnancy and Lactation?: Evidence to Date

By Majithia Raj

Drugs, Vol. 72, Iss. 2, 2012-01 ,pp. : 171-179

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors in Osteoporosis: Do They Reduce the Risk of Fracture?

By Schlienger R.G. Meier C.R.

Drugs & Aging, Vol. 20, Iss. 5, 2003-01 ,pp. : 321-336

Adis International

Access to resources Recommend Favorite

The osteoporosis and fracture risk for over the counter (OTC) proton pump inhibitors (PPIs) has been revoked by the FDA

Reactions Weekly, Vol. 1, Iss. 1345, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite